Name: TAMIFLU
Presentation:
- Capsules (yellow: 30 mg; gray: 45 mg, yellow and gray: 75 mg)
- Powder for oral suspension (12 mg / ml).
Directions:
- In the treatment of influenza, it can be used in patients who show symptoms of the flu, when we know that the virus circulates within the community.
- In the prevention of influenza, it can be used in patients who had contact with a person sticking.
This use is generally determined on a case by case but may, in exceptional circumstances, take the form of a season. For example, vaccination against influenza, and insufficient pandemic (epidemic influenza worldwide).
Caution: Tamiflu does not replace vaccination against influenza and its use must be based on official recommendations.
Dosage:
- Treatment of influenza (initiated within two days after onset of symptoms): a dose taken twice daily for five days.
- Prevention of influenza (initiated within two days after contact with someone with the flu): One dose taken once daily for at least 10 days after contact with an infected person.
- Epidemic influenza: a dose of Tamiflu may be taken for a maximum period of six weeks.
The dose of Tamiflu ® is 75 mg for an adult or child over 40 kg. For a child under 40 kg, the dose is adjusted according to weight using low-dose capsules (30 or 45 mg) or suspension (if the child can not swallow capsules).
Administrative Procedures:
Oral
Caution:
Tamiflu ® should not be used in children under one year. Doses should be reduced in patients suffering from kidney problems.
Drug Interactions:
Tamiflu ® should not be used in people who are hypersensitive (allergic) to oseltamivir.
Side effects:
- Headache
- Nausea
- Vomiting and diarrhea (especially children)
Policy Statement:
The active ingredient of Tamiflu ®, oseltamivir, acts specifically on the virus of influenza by inhibiting certain enzymes present on its surface, called neuraminidase. When neuraminidase is inhibited, the spread of infection is halted. Oseltamivir acts both on the neuraminidase of virus influenza type A (most common) and those of virus influenza type B.
Pregnancy and lactation:
There are no adequate data on the use of oseltamivir in pregnant women. Oseltamivir should be used during pregnancy only if the benefit to the mother justifies the potential risk to the fetus. Oseltamivir should be used during breastfeeding if the benefit to the mother justifies the potential risk to the breastfed infant.
Studies to date:
- Treatment: The effects of Tamiflu ® were first tested in experimental models before being studied in humans. In it, Tamiflu ® was compared with placebo (a dummy treatment) in studies evaluating the treatment of influenza (2 413 adults and adolescents, 741 patients and 1 033 children). Efficacy was measured using a scorecard on which the patients recorded their symptoms (feeling of fever, muscle aches, headache, sore throat, cough, malaise and runny nose).
- Prevention of influenza: Tamiflu ® has been studied in people who were exposed to the disease after a family member had contracted the flu (962 cases) or during an epidemic (1 562 individuals aged 16 55 years and 548 elderly people in nursing homes). The study measured the incidence of influenza as demonstrated by laboratory tests. One study also examined the use of Tamiflu ® in a family (277 families), both for treating the person with the flu for the treatment or prevention of influenza among persons in contact with the patient.
The effects shown to date:
- Treatment in adults: the use of Tamiflu ® has reduced the duration of illness of 4.2 days against 5.2 days for patients on placebo. Among children aged one to six years, duration of disease was reduced by 1.5 days.
- Prevention: Tamiflu ® reduced the incidence of influenza among persons in contact with a person sticking. In the study during an epidemic, 1% of people taking Tamiflu ® have developed the flu after contact, against 5% of those on placebo. In families with a person with the flu, 7% of household members have developed the flu after receiving preventive treatment with Tamiflu ®, as against 20% among those who did not receive preventive treatment.
Why Tamiflu ® has been approved?
The flu is seasonal normally handled through vaccination. The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Tamiflu ® outweigh its risks for treatment and prevention of influenza, as a complementary method used in a pandemic or when vaccines against the flu are not effective against the virus of avian origin with seasonal epidemics.
More information on Tamiflu:
The European Commission has granted a permission marketing valid throughout the European Union for Tamiflu ® Roche Registration Limited June 20, 2002. Permission marketing was renewed June 20, 2007.
Issue:
The drug is issued with a prescription.
Presentation:
- Capsules (yellow: 30 mg; gray: 45 mg, yellow and gray: 75 mg)
- Powder for oral suspension (12 mg / ml).
Directions:
- In the treatment of influenza, it can be used in patients who show symptoms of the flu, when we know that the virus circulates within the community.
- In the prevention of influenza, it can be used in patients who had contact with a person sticking.
This use is generally determined on a case by case but may, in exceptional circumstances, take the form of a season. For example, vaccination against influenza, and insufficient pandemic (epidemic influenza worldwide).
Caution: Tamiflu does not replace vaccination against influenza and its use must be based on official recommendations.
Dosage:
- Treatment of influenza (initiated within two days after onset of symptoms): a dose taken twice daily for five days.
- Prevention of influenza (initiated within two days after contact with someone with the flu): One dose taken once daily for at least 10 days after contact with an infected person.
- Epidemic influenza: a dose of Tamiflu may be taken for a maximum period of six weeks.
The dose of Tamiflu ® is 75 mg for an adult or child over 40 kg. For a child under 40 kg, the dose is adjusted according to weight using low-dose capsules (30 or 45 mg) or suspension (if the child can not swallow capsules).
Administrative Procedures:
Oral
Caution:
Tamiflu ® should not be used in children under one year. Doses should be reduced in patients suffering from kidney problems.
Drug Interactions:
Tamiflu ® should not be used in people who are hypersensitive (allergic) to oseltamivir.
Side effects:
- Headache
- Nausea
- Vomiting and diarrhea (especially children)
Policy Statement:
The active ingredient of Tamiflu ®, oseltamivir, acts specifically on the virus of influenza by inhibiting certain enzymes present on its surface, called neuraminidase. When neuraminidase is inhibited, the spread of infection is halted. Oseltamivir acts both on the neuraminidase of virus influenza type A (most common) and those of virus influenza type B.
Pregnancy and lactation:
There are no adequate data on the use of oseltamivir in pregnant women. Oseltamivir should be used during pregnancy only if the benefit to the mother justifies the potential risk to the fetus. Oseltamivir should be used during breastfeeding if the benefit to the mother justifies the potential risk to the breastfed infant.
Studies to date:
- Treatment: The effects of Tamiflu ® were first tested in experimental models before being studied in humans. In it, Tamiflu ® was compared with placebo (a dummy treatment) in studies evaluating the treatment of influenza (2 413 adults and adolescents, 741 patients and 1 033 children). Efficacy was measured using a scorecard on which the patients recorded their symptoms (feeling of fever, muscle aches, headache, sore throat, cough, malaise and runny nose).
- Prevention of influenza: Tamiflu ® has been studied in people who were exposed to the disease after a family member had contracted the flu (962 cases) or during an epidemic (1 562 individuals aged 16 55 years and 548 elderly people in nursing homes). The study measured the incidence of influenza as demonstrated by laboratory tests. One study also examined the use of Tamiflu ® in a family (277 families), both for treating the person with the flu for the treatment or prevention of influenza among persons in contact with the patient.
The effects shown to date:
- Treatment in adults: the use of Tamiflu ® has reduced the duration of illness of 4.2 days against 5.2 days for patients on placebo. Among children aged one to six years, duration of disease was reduced by 1.5 days.
- Prevention: Tamiflu ® reduced the incidence of influenza among persons in contact with a person sticking. In the study during an epidemic, 1% of people taking Tamiflu ® have developed the flu after contact, against 5% of those on placebo. In families with a person with the flu, 7% of household members have developed the flu after receiving preventive treatment with Tamiflu ®, as against 20% among those who did not receive preventive treatment.
Why Tamiflu ® has been approved?
The flu is seasonal normally handled through vaccination. The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Tamiflu ® outweigh its risks for treatment and prevention of influenza, as a complementary method used in a pandemic or when vaccines against the flu are not effective against the virus of avian origin with seasonal epidemics.
More information on Tamiflu:
The European Commission has granted a permission marketing valid throughout the European Union for Tamiflu ® Roche Registration Limited June 20, 2002. Permission marketing was renewed June 20, 2007.
Issue:
The drug is issued with a prescription.
0 comments:
Post a Comment